← Eichor
Study identifier: NCT06675552 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany

Condition: Heart Disease · Heart Failure · Cardiovascular Disease  ·  Sponsor: AstraZeneca

PhaseN/A
Planned participants438
Who can joinAll sexes, 18 Years to 130 Years
Healthy volunteersNo

About this study

Heart failure (HF) is a global public health issue that affects more than 63 million people worldwide. The clinical and economic burden of HF on health care systems is substantial. Heart failure with reduced ejection fraction (HFrEF) represents approximately 50% of the HF patient population.The burden of HF is expected to increase substantially as the population ages, and despite improvements in treatment, hospitalisation and mortality rates remain especially high in HFrEF patients. The current guideline recommendation of directed medical therapy for HFrEF combines four drug classes with proven prognostic benefit: Angiotensin receptor-neprilysin inhibitor (ARNI)/angiotensin converting enzyme inhibitors (ACE I)/angiotensin receptor blockers (ARB), betablockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i). The 2023 ESC (European Society of Cardiology) HF guideline update additionally recommends a rapid in-hospital sequencing approach of guideline-directed medical therapy (GDMT) with frequent physician visits during the first 6 weeks post discharge. Studies investigating the implementation of GDMT in a real-world setting have shown that a significant proportion of patients did not receive the recommended drug combination therapy. Delayed initiation of GDMT contributes to the low number of patients receiving guideline concordant HFrEF therapy, which ultimately may affect patient outcomes. One approach to implement the…

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center  ·  1-877-240-9479  ·  information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (6)

Research SiteBerlin, GermanyRecruiting
Research SiteErfurt, GermanyRecruiting
Research SiteGifhorn, GermanyRecruiting
Research SiteLeipzig, GermanyRecruiting
Research SiteSchwerin, GermanyRecruiting
Research SiteWuppertal, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06675552